secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001193125-26-000905
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Biopharma Chief Development Officer Qing Zuraw departs Dec 31; gets $565K severance + consulting
--------------------------------------------------------------------------------

- Dr. Qing Zuraw, Chief Development Officer, resigned effective Dec 31, 2025 to pursue other opportunities.
- Separation pay of $565,000 (12 months) plus $115,724 prorated 2025 target bonus; retains $100K signing bonus.
- All unvested stock options and RSUs forfeited (no vesting before one-year anniversary).
- Company expects to enter a consulting arrangement with Zuraw for Q1 2026 to assist transition.
- Separation includes 12-month non-compete, non-disparagement, and standard confidentiality covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526000905/0001193125-26-000905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526000905/vor-20251231.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-000905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer